Caixin
Caixin Global – Latest China News & Headlines

Home >

ABOUT US

CX Tech is Caixin Global's real-time tech news portal, featuring 24-hour news, short-form analysis, and roundups from business and tech media in China.

TRENDING
In Depth: What’s in the China-U.S. Tariff Truce, and What’s Left Unsettled
LATEST
Huawei Launches AI-Focused Smartphone Sub-Brand OSTA
U.S. Cleared Nearly 880,000 AI Chips for Chinese Buyers
Alibaba Lowers Cloud Growth Outlook After U.S. Chip Curbs
DeepSeek Closes 100 Billion Yuan Funding Round
U.S. Trade, Investment Restrictions on China Could Remain Under Democratic Congress, Business Group Chief Says
Tencent, ByteDance Report Millions of Daily Users for AI Office Tools
Nvidia to Stop Selling Advanced AI Chips to China
In Depth: DeepSeek’s Computing Crunch Pushes China’s AI Developers Beyond Models
Organizational Overhaul Is Key to Reaping Benefits of AI, Baidu Chief Says
Nearing AI Robotics Breakthrough Would Strain Production, Unitree Founder Says
Wingtech to Appeal Dutch Court Order in Nexperia Control Dispute
Caixin Summit: China’s AI Push Needs More Than Better Model Rankings
CATL Expands Aviation Battery Push as eVTOL Market Takes Shape
Moonshot Executive Says AI Agents Could Handle Long-Horizon Tasks Within Months
Baidu’s Robin Li Urges Companies to Reorganize Around AI
Spain Pushes for TikTok Suspension Over Child Abuse Content
Alibaba Files to Spin Off Chip Unit in Hong Kong
Chinese Venture Plans Orbital Computing Network
In Depth: CEO’s Affair Pulls Nvidia Deeper Into the U.S.-China Chip Fight
Zeiss Deepens China Push With Locally Developed Eye Care Products
Chinese DNA Sequencing Firm BGI Faces Legal Battle with Illumina

By Wang Luyao and Han Wei / May 24, 2019 02:59 AM / Business & Tech

Photo: VCG

Photo: VCG

Chinese genomics giant BGI Group said it is prepared in the face of rising legal disputes in Europe and may resort to counterclaims to fight patent infringement allegations.

BGI is “actively responding to recent patent disputes and will take corresponding legal actions,” BGI said in a statement to Caixin Thursday, adding that it “will not rule out the use of legal weapons such as counterclaims to protect its legal rights.”

BGI’s subsidiary BGI Europe was sued by Illumina Inc. in Denmark on alleged patent infringement last week. The complaint alleged BGI's sequencing products and related sequencing chemistry reagents infringe on Illumina's European patent.

The case followed another infringement suit filed by Illumina in Germany against another BGI subsidiary, Latvia MGI Tech, in March.

In the statement, BGI said it is confident in its own technology, which cost billions of yuan to develop and “broke the market monopoly in the upstream genome sequencing market.”

When interviewed by Caixin earlier this month on whether Illumina will file more suits against BGI outside Europe, the company’s Chief Commercial Officer Mark Van Oene said Illumina will continue pursuing patent protection, without elaborating.

Established in 1999, BGI was a client of Illumina’s sequencing equipment but has started to develop its own devices after purchasing U.S. genomics company Complete Genomics in 2012.

Related: BGI Genomics’ Profits Slip As Questions Linger About Its Services


Share this article
Open WeChat and scan the QR code